SunTrust analyst David MacDonald lowered his price target on LabCorp to $175 after the company cut its FY18 guidance last week amid "slower growth in referred direct-to-consumer genetic testing" along with lower hospital and health system referrals. The analyst also expects the company's 2019 to be a "bit of a grind", but sees its long-term positive lab industry fundamentals remaining "intact" and maintains his Buy rating. MacDonals adds that the incremental pressure related to "Protecting Access to Medicare Act" legislation "likely drives share gain opportunity and further accelerates potential M&A" for LabCorp.